Trial Profile
Risankizumab Versus Placebo in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment in the Russian Federation (IMMpress)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Aug 2022
Price :
$35
*
At a glance
- Drugs Risankizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms IMMPRESS
- Sponsors AbbVie
- 02 Aug 2022 Results from the period A, published in the Dermatology and Therapy.
- 17 Feb 2020 Status changed from active, no longer recruiting to completed.
- 27 Dec 2019 Planned End Date changed from 5 Feb 2020 to 11 Feb 2020.